Skip to main content

Table 3 Probability of target attainment of selective levofloxacin dosing regimens for Gram-positive infection with S. pneumoniae a in 5000 virtual patients with 8-h hemodialysis PIRRT at dialysate flow rate of 5 L/h during the initial 72 h

From: In silico trials using Monte Carlo simulation to evaluate ciprofloxacin and levofloxacin dosing in critically ill patients receiving prolonged intermittent renal replacement therapy

Dosing regimens Early PIRRTb Late PIRRTc
Day 1 PTA (%) Day 2 PTA (%) Day 3 PTA (%) Mean PTA (%) Day 1 PTA (%) Day 2 PTA (%) Day 3 PTA (%) Mean PTA (%)
Levofloxacin
500 mg q48h 33.2 0.0 66.0 33 50.0 0.0 76.8 43.5
500 mg q24h 32.4 82.3 93.6 69.4 49.2 87.7 96.3 77.7
750 mg LD, then 250 mg q24h post-PIRRT 90.3 85.5 78.4 84.7 82.4 78.4 73.9 78.3
750 mg LD, then 500 mg q24h post-PIRRT 96.2 98.3 99.0 97.8 83.6 94.6 97.7 91.9
750 mg LD, then 750 mg q24h post-PIRRT 98.8 99.9 99.9 99.6 84.1 98.8 99.9 94.3
  1. Bolded dosing regimens are the ones that attained PTA of ~90 % or greater in both early and late PIRRT, using the smallest daily dose
  2. LD loading dose
  3. aPharmacodynamic target used for Gram-positive infection was AUC24h:MIC ≥50 with MIC = 2 mg/L for levofloxacin (susceptibility breakpoint for Streptococcus pneumoniae)
  4. bEarly PIRRT: when the first fluoroquinolone dose is administered with the commencement of a daily PIRRT session
  5. cLate PIRRT: when the first fluoroquinolone dose is administered 16 h before a daily PIRRT session